Matches in SemOpenAlex for { <https://semopenalex.org/work/W2249763140> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- W2249763140 abstract "e11076 Background: The National Comprehensive Cancer Network (NCCN) guidelines recommend trastuzumab- or lapatinib-based therapies as the preferred agents for metastatic HER2-positive breast cancer. Few studies have compared treatment patterns and outcomes in MBC patients (pts) treated with trastuzumab vs. lapatinib. The objective of this study is to compare rates of new metastatic sites, discontinuation, healthcare resource utilization, and costs in MBC pts initiated on lapatinib vs trastuzumab. Methods: Adult women with MBC initiated on trastuzumab or lapatinib on or after 03/13/2007 (lapatinib FDA-approval date) were selected in the PharMetrics® Integrated Database (2000-2011). Pts were followed from trastuzumab or lapatinib initiation date up to the end of continuous healthcare plan enrollment/data availability, whichever occurred first. New metastatic sites and discontinuation rates (gap ≥45 consecutive days) were compared among trastuzumab and lapatinib pts using multivariate Cox proportional-hazards models. Incremental healthcare resource utilization and monthly costs (2010 USD; measured from a payer perspective) were estimated using multivariate generalized linear models. Results: Among the643 pts selected, 381 and 262 pts were initiated on trastuzumab and lapatinib, respectively. After multivariate adjustment, compared to trastuzumab pts, lapatinib pts had a higher rate of new metastases (hazard ratio [HR]=1.65; p<.001) and treatment discontinuation (HR=1.57; p<.001). There was no statistically significant difference in total healthcare cost between lapatinib and trastuzumab pts (p=.397). The incidence of medical visits associated with treatment administration was lower in lapatinib pts (Incidence rate ratio [IRR]=0.34; p<.001), however, the incidence of other outpatient visits was significantly higher in lapatinib pts (IRR=1.19; p<.001). Conclusions: Whileboth cohorts presented similar healthcare costs, pts initiated on lapatinib showed higher rates of new metastatic sites, discontinuation, more outpatient visits (non treatment-related), but fewer medical visits associated with treatment administration." @default.
- W2249763140 created "2016-06-24" @default.
- W2249763140 creator A5032187510 @default.
- W2249763140 creator A5039045250 @default.
- W2249763140 creator A5040026787 @default.
- W2249763140 creator A5041026389 @default.
- W2249763140 creator A5072015843 @default.
- W2249763140 creator A5089194015 @default.
- W2249763140 date "2012-05-20" @default.
- W2249763140 modified "2023-09-26" @default.
- W2249763140 title "Comparison of treatment patterns and outcomes in metastatic breast cancer (MBC) patients initiated on trastuzumab versus lapatinib: A retrospective analysis." @default.
- W2249763140 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e11076" @default.
- W2249763140 hasPublicationYear "2012" @default.
- W2249763140 type Work @default.
- W2249763140 sameAs 2249763140 @default.
- W2249763140 citedByCount "0" @default.
- W2249763140 crossrefType "journal-article" @default.
- W2249763140 hasAuthorship W2249763140A5032187510 @default.
- W2249763140 hasAuthorship W2249763140A5039045250 @default.
- W2249763140 hasAuthorship W2249763140A5040026787 @default.
- W2249763140 hasAuthorship W2249763140A5041026389 @default.
- W2249763140 hasAuthorship W2249763140A5072015843 @default.
- W2249763140 hasAuthorship W2249763140A5089194015 @default.
- W2249763140 hasConcept C121608353 @default.
- W2249763140 hasConcept C126322002 @default.
- W2249763140 hasConcept C143998085 @default.
- W2249763140 hasConcept C167135981 @default.
- W2249763140 hasConcept C2775930923 @default.
- W2249763140 hasConcept C2777329042 @default.
- W2249763140 hasConcept C2779786085 @default.
- W2249763140 hasConcept C530470458 @default.
- W2249763140 hasConcept C71924100 @default.
- W2249763140 hasConceptScore W2249763140C121608353 @default.
- W2249763140 hasConceptScore W2249763140C126322002 @default.
- W2249763140 hasConceptScore W2249763140C143998085 @default.
- W2249763140 hasConceptScore W2249763140C167135981 @default.
- W2249763140 hasConceptScore W2249763140C2775930923 @default.
- W2249763140 hasConceptScore W2249763140C2777329042 @default.
- W2249763140 hasConceptScore W2249763140C2779786085 @default.
- W2249763140 hasConceptScore W2249763140C530470458 @default.
- W2249763140 hasConceptScore W2249763140C71924100 @default.
- W2249763140 hasLocation W22497631401 @default.
- W2249763140 hasOpenAccess W2249763140 @default.
- W2249763140 hasPrimaryLocation W22497631401 @default.
- W2249763140 isParatext "false" @default.
- W2249763140 isRetracted "false" @default.
- W2249763140 magId "2249763140" @default.
- W2249763140 workType "article" @default.